Colon News and Research

RSS

$S*BIO begins SB1317 Phase 1 clinical trial in patients with advanced/refractory hematologic malignancies$

S*BIO begins SB1317 Phase 1 clinical trial in patients with advanced/refractory hematologic malignancies

S*BIO Pte Ltd today announced that a fourth novel, potential best-in-class compound discovered and developed by S*BIO has entered a Phase 1 clinical trial. The initiation of the study for S*BIO's oral multi-kinase inhibitor, SB1317 or TG02, in patients with advanced/refractory hematologic malignancies has triggered a payment from S*BIO's development and commercialization partner for the program, Tragara Pharmaceuticals.

22 Nov 2010

IsoRay to sell $2.25 million in common stock

IsoRay Inc. has entered a securities purchase agreement with an investor to sell $2.25 million in common stock with the potential of $2,075,000 additional funding through two subsequent short term warrant tranches of 90 days and 180 days assuming an average exercise price of $1.40 and that all Series A and B warrants are exercised. Additional funding will occur if Series C or D warrants are exercised.

22 Nov 2010

FDA-approved anti-parasite drug blocks Wnt signaling pathway in colon cancer

An old pinworm medicine is a new lead in the search for compounds that block a signaling pathway implicated in colon cancer. The findings, reported by Vanderbilt University Medical Center researchers in the November issue of Nature Chemical Biology, suggest a fresh approach for developing therapeutics that target the pathway.

20 Nov 2010

Yorkshire scientist wins national medical award for surgical improvement in colon cancer

A Yorkshire Cancer Research scientist has earned himself a national medical award for helping pioneer life-saving surgical improvements to the way tumours are removed from colon cancer patients.

18 Nov 2010

EDP Biotech introduces new blood test for detecting early-stage colon cancer at Medica trade fair

The future of colon cancer screening may be surprisingly simple. ColoMarker, an innovative blood test to detect the early stages of colon cancer is generating plenty of attention from a wide audience, including from some of the world's leading researchers in cancer biomarkers and gastrointestinal medicine.

18 Nov 2010

Cancer patients can still access NICE rejected drugs

Anti cancer drugs that have been rejected by the UK Government’s new cancer drugs fund would still be available to needy patients according to the new ‘top-up’ cash plan that is being launched. This Health Top-Up cash plan comes from Western Provident Association (WPA).

17 Nov 2010

Aeterna Zentaris presents results of orally active compounds with anti-tumor effects at EORTC-NCI-AACR Symposium

Aeterna Zentaris Inc. today presented posters on encouraging preclinical results for AEZS-129 and AEZS-132, two novel orally active compounds with anti-tumor effects.

17 Nov 2010

Targeted therapies could treat a broad range of cancers: Research

Targeted cancer therapies such as trastuzumab (Herceptin), gefitinib (Iressa) and erlotinib (Tarceva) could be used to treat a wider range of cancers than previously thought, according to new research presented today (Wednesday) at the 22nd EORTC-NCI-AACR [1] Symposium on Molecular Targets and Cancer Therapeutics in Berlin.

17 Nov 2010

Enzon presents data on three investigational mRNA antagonists at EORTC-NCI-AACR Symposium

Enzon Pharmaceuticals, Inc. today presented data from preclinical studies of three investigational messenger RNA (mRNA) antagonists. These antagonists are based on the locked nucleic acid (LNA) technology platform targets licensed from Santaris Pharma A/S.

17 Nov 2010

Risk reduction of 20 ailments with regular exercise: Review

In a review article researchers have concluded that regular exercise cuts the risk of more than 20 illnesses. Some of these include colon cancer, heart disease, diabetes, osteoporosis and stroke said the study published in the International Journal of Clinical Practice.

16 Nov 2010

New inhalable dry powder treatment for lung cancer shows significant increase in survival rates: Research

A new inhalable dry powder treatment for lung cancer shows a significant increase in survival rates and is far less invasive than current treatment options, which frequently include radiation and surgery. This research is being presented at the 2010 International Pharmaceutical Federation Pharmaceutical Sciences World Congress in association with the American Association of Pharmaceutical Scientists Annual Meeting and Exposition in New Orleans, La., Nov. 14-18.

16 Nov 2010

Regular exercise could reduce risk of developing physical, mental health conditions

People who take regular exercise could reduce their risk of developing around two dozen physical and mental health conditions including some cancers and dementia and slow down how quickly their body deteriorates as they age.

15 Nov 2010

New mathematical model may help predict anemia risk

A collaboration between a physician-researcher at Massachusetts General Hospital (MGH) and a mathematician from Harvard University has led to development of a mathematical model reflecting how red blood cells change in size and hemoglobin content during their four-month lifespan.

15 Nov 2010

Exiqon publishes clinical study data on colon cancer

Exiqon A/S today published data from a clinical study that stratifies colon cancer patients into groups of high, medium and low chances of survival which may prove useful for optimizing the treatment of each individual cancer patient.

14 Nov 2010

CytomX awarded $488,000 as grant under QTDP Program

CytomX Therapeutics, a biotechnology company focused on the development of proteolytically activated antibodies, today announced the receipt of two grants totaling more than $488,000 from the Qualifying Therapeutic Discovery Project (QTDP) Program. The grants are directed toward the company's lead preclinical programs targeting colon, head and neck, pancreatic and triple-negative breast cancers and glioblastoma multiforme (GBM).

12 Nov 2010

SU2C to receive second CLIO Healthcare Award

The CLIO Healthcare Awards will present its second annual honorary award, to Stand Up To Cancer (SU2C), on November 12th, 2010. This dedicated award celebrates an organization or individual for excellence in healthcare communications and for contributing to the improvement of public health.

12 Nov 2010

FDA grants SEDASYS System appeal

Ethicon Endo-Surgery, Inc. (EES) today announced that the Commissioner's Office of the U.S. Food and Drug Administration (FDA) has granted the appeal of the Center for Devices and Radiological Health's (CDRH) denial of the SEDASYS System Premarket Approval Application (PMA). As a result, a new Independent Advisory Panel will be appointed to reconsider the SEDASYS System clinical trial data and application.

11 Nov 2010

Novel mechanism regulating circadian rhythm identified

Scientists from the Florida campus of The Scripps Research Institute have identified for the first time a novel mechanism that regulates circadian rhythm, the master clock that controls the body's natural 24-hour physiological cycle. These new findings could provide a new target not only for jet lag, shift work, and sleep disturbances, but also for disorders that result from circadian rhythm disruption, including diabetes and obesity as well as some types of cancer.

11 Nov 2010

4SC 2010 first nine months revenue decreases from EUR1.4 million to EUR0.8 million

4SC, a drug discovery and development company focused on autoimmune and cancer indications, today announced its financial results in accordance with International Financial Reporting Standards (IFRS) for the first nine months of 2010, which ended on 30 September 2010.

11 Nov 2010

Dana-Farber lends iPads to cancer patients to help them pass the time in clinic

Andrea Casella comes to Dana-Farber Cancer Institute every week for chemotherapy to treat her lung cancer. It's a full day. Recognizing that patients can spend hours in the clinic for treatment and tests, Dana-Farber has started lending iPads to patients like Casella to help them pass the time.

11 Nov 2010

Colon News and Research

S*BIO begins SB1317 Phase 1 clinical trial in patients with advanced/refractory hematologic malignancies

IsoRay to sell $2.25 million in common stock

FDA-approved anti-parasite drug blocks Wnt signaling pathway in colon cancer

Yorkshire scientist wins national medical award for surgical improvement in colon cancer

EDP Biotech introduces new blood test for detecting early-stage colon cancer at Medica trade fair

Cancer patients can still access NICE rejected drugs

Aeterna Zentaris presents results of orally active compounds with anti-tumor effects at EORTC-NCI-AACR Symposium

Targeted therapies could treat a broad range of cancers: Research

Enzon presents data on three investigational mRNA antagonists at EORTC-NCI-AACR Symposium

Risk reduction of 20 ailments with regular exercise: Review

New inhalable dry powder treatment for lung cancer shows significant increase in survival rates: Research

Regular exercise could reduce risk of developing physical, mental health conditions

New mathematical model may help predict anemia risk

Exiqon publishes clinical study data on colon cancer

CytomX awarded $488,000 as grant under QTDP Program

SU2C to receive second CLIO Healthcare Award

FDA grants SEDASYS System appeal

Novel mechanism regulating circadian rhythm identified

4SC 2010 first nine months revenue decreases from EUR1.4 million to EUR0.8 million

Dana-Farber lends iPads to cancer patients to help them pass the time in clinic

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News